Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CREON Clear all
Terminated Phase 2 Interventional Results available

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

NCT03469258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancrelipase
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

NCT00559364
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Pancreatectomy
Interventions
Viokase® 16, Placebo, Proton pump inhibitor (PPI), Omeprazole
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 7, 2026, 3:02 PM EDT
Terminated Phase 1 Interventional Results available

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

NCT01142128
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 7, 2026, 3:02 PM EDT
Not listed Not applicable Interventional

Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

NCT01771146
View directory record Official record
Conditions
Pancreas Cancer, Localized Pancreas Cancer, Non-metastatic Pancreas Cancer
Interventions
FOLFIRINOX Regimen
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

NCT05069597
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Pancreatitis
Interventions
CREON
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 7, 2026, 3:02 PM EDT
Completed No phase listed Observational

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

NCT04949828
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
CREON
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Stanford, California • Gainesville, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Early Phase 1 Interventional Results available

Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes

NCT05266963
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CREON, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT00788593
View directory record Official record
Conditions
Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions
Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT00981214
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 7 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 7, 2026, 3:02 PM EDT
Withdrawn Phase 2 Interventional

Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis

NCT02706236
View directory record Official record
Conditions
Pancreatitis
Interventions
Pancrelipase, placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03924947
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Ventura, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 7, 2026, 3:02 PM EDT
Terminated Phase 4 Interventional

Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control

NCT00744250
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT00775528
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
1 Month to 6 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Sep 7, 2026, 3:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

NCT04098237
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Pancrelipase
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

NCT02372383
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ethambutol, Rifampin, Azithromycin, Pancrelipase
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

NCT00559052
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
VIOKASE 16
Drug
Lead sponsor
Axcan Pharma
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida • Mayo Clinic- Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

NCT00690820
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
7 Years to 11 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
10
States / cities
Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

PR-018: An Open-Label, Safety Extension of Study PR-011

NCT01131507
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 12 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

NCT00662675
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes, Cystic Fibrosis
Interventions
Pancrease MT 10.5, or MT 21, Placebo for Pancrease MT 10.5 or MT 21
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
7 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 7, 2026, 3:02 PM EDT